The knowledge that helps Danny stay a step ahead of a hereditary cancer

Meet Danny, a cancer survivor from Roxboro, North Carolina. In 2017, his optometrist noted a freckle in his right eye and said they’d simply keep an eye on it. By his 2021 visit, it had changed — and his doctor referred him to Duke Eye Center, where he was diagnosed with a small ocular melanoma. After plaque radiation and tumor removal, his care team sent a biopsy to Castle Biosciences for DecisionDx-UM testing. His result came back Class 2, placing him in a higher-risk category. Researching his family history, Danny also learned that his grandmother’s death from liver cancer had been caused by an undiagnosed ocular melanoma — meaning his own diagnosis was likely hereditary. Rather than feel defeated by the high-risk result, Danny has used it to stay on schedule with his surveillance scans, taking each day as it comes with his wife by his side.

‍